Fiscal 3rd Quarter 2026
Filed Aug 13, 2026Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Edesa completed preparations for its Phase 2 EB06 vitiligo study and reported positive exploratory paridiprubart data in ARDS patients with acute kidney injury, but quarterly operating expenses and net loss increased substantially from the prior-year period.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total operating expenses, three months ended June 30, 2026GAAP | $5.5 million | – | increased by $3.6 million |
| Research and development expenses, three months ended June 30, 2026GAAP | $4.0 million | – | increased by $3.1 million |
| General and administrative expenses, three months ended June 30, 2026GAAP | $1.6 million | – | increased by $0.6 million |
| Loss from operations, three months ended June 30, 2026GAAP | $ (5,519,549 ) | – | – |
| Reimbursement grant income, three months ended June 30, 2026GAAP | 107,368 | – | – |
| Other income (loss), three months ended June 30, 2026GAAP | 111,938 | – | – |
| Total other income, three months ended June 30, 2026GAAP | $112,000 | – | decreased by approximately $42,000 |
| Income tax expense, three months ended June 30, 2026GAAP | - | – | – |
| Net loss, three months ended June 30, 2026GAAP | $5.4 million | – | – |
| Loss per common share - basic and diluted, three months ended June 30, 2026GAAP | $ (0.60 ) | – | – |
| Weighted average number of common shares, three months ended June 30, 2026GAAP | 9,007,474 | – | – |
| Total operating expenses, nine months ended June 30, 2026GAAP | $12.2 million | – | increased by $6.8 million |
| Research and development expenses, nine months ended June 30, 2026GAAP | $7.8 million | – | increased by $5.4 million |
| General and administrative expenses, nine months ended June 30, 2026GAAP | $4.3 million | – | increased by $1.3 million |
| Loss from operations, nine months ended June 30, 2026GAAP | $ (12,157,926 ) | – | – |
| Reimbursement grant income, nine months ended June 30, 2026GAAP | 276,021 | – | – |
| Other income (loss), nine months ended June 30, 2026GAAP | 285,114 | – | – |
| Total other income, nine months ended June 30, 2026GAAP | $285,000 | – | decreased by $200,000 |
| Income tax expense, nine months ended June 30, 2026GAAP | 800 | – | – |
| Net loss, nine months ended June 30, 2026GAAP | $11.9 million | – | – |
| Loss per common share - basic and diluted, nine months ended June 30, 2026GAAP | $ (1.40 ) | – | – |
| Weighted average number of common shares, nine months ended June 30, 2026GAAP | 8,504,968 | – | – |
What drove it
- Research and development expense increased primarily because of manufacturing-related activities and other preparations for the planned Phase 2 clinical study of EB06 in vitiligo patients, as well as increased unallocated research costs.
- Increased research and development expenses were partially offset by decreased expenditures for the paridiprubart program.
- General and administrative expense increased primarily due to increases in noncash share-based compensation and professional fees.
- Other income declined primarily due to lower reimbursement funding from the Canadian government's Strategic Response Fund, partially offset by a favorable impact from foreign currency exchange.
- The company completed preparations for its Phase 2 clinical study of EB06 in moderate-to-severe nonsegmental vitiligo.
- In ARDS patients with concurrent acute kidney injury, paridiprubart plus standard of care was associated with significant mortality reductions supported by concordant improvements in the kidney-specific MAKE30 composite endpoint.
Concerns
- The company reported a net loss of $5.4 million for the quarter, compared to a net loss of $1.7 million for the quarter ended June 30, 2025.
- Total operating expenses increased to $5.5 million from $1.9 million in the prior-year quarter.
- Total other income decreased to $112,000 from $154,000 in the prior-year quarter.
- The company stated that recruitment is expected to begin in the coming weeks in Canada, with additional jurisdictions subject to regulatory approval and administrative filings.
- The filing identifies risks related to access to sufficient capital, regulatory approvals, clinical effectiveness, intellectual property, and regulatory filings.
What to watch
- Initiation of patient recruitment and enrollment for the Phase 2 EB06 vitiligo study in Canada.
- Activation of additional investigational sites and jurisdictions, subject to regulatory approval and administrative filings.
- Potential regulatory pathways in major markets for paridiprubart.
- Strategic and business development discussions with potential partners for paridiprubart.
- The shift in spending from preparatory activities toward clinical trial execution.
- The H.C. Wainwright 28th Annual Global Investment Conference to be held September 12-13, 2026 in New York, NY.
Balance sheet and cash flow
- Cash and cash equivalents at June 30, 2026: $10.3 million.
- Working capital at June 30, 2026: $6.9 million.
- Cash and cash equivalents: $ 10,332,520 at June 30, 2026; $ 10,792,172 at September 30, 2025.
- Other current assets: 447,758 at June 30, 2026; 720,704 at September 30, 2025.
- Non-current assets: 1,940,917 at June 30, 2026; 2,017,642 at September 30, 2025.
- Total Assets: $ 12,721,195 at June 30, 2026; $ 13,530,518 at September 30, 2025.
- Current liabilities: $ 3,910,041 at June 30, 2026; $ 1,078,536 at September 30, 2025.
- Shareholders' equity: 8,811,154 at June 30, 2026; 12,451,982 at September 30, 2025.
- Net cash used in operating activities for the nine months ended June 30, 2026: $ (7,186,629 ); prior-year period: $ (5,601,268 ).
- Net cash provided by financing activities for the nine months ended June 30, 2026: 6,793,376; prior-year period: 16,844,415.
- Net change in cash and cash equivalents for the nine months ended June 30, 2026: (459,652); prior-year period: 11,324,370.
- Cash and cash equivalents, beginning of period: 10,792,172; prior-year period: 1,037,320.
- Cash and cash equivalents, end of period: $ 10,332,520; prior-year period: $ 12,361,690.
Analysis
Edesa remains a clinical-stage company, and the release reported no revenue or commercial segments. The quarter centered on operational advancement: the company completed preparations for the Phase 2 EB06 study in moderate-to-severe nonsegmental vitiligo and, subsequent to quarter-end, began activating its first investigational sites. Management expects recruitment to begin in the coming weeks in Canada, while further jurisdictions remain subject to regulatory approval and administrative filings.
Spending rose materially as the EB06 program moved from preparation toward execution. Total operating expenses increased by $3.6 million to $5.5 million in the three months ended June 30, 2026. Research and development expenses increased by $3.1 million to $4.0 million, driven by manufacturing-related activities, study preparation and increased unallocated research costs, partly offset by lower paridiprubart spending. General and administrative expenses increased by $0.6 million to $1.6 million, primarily from noncash share-based compensation and professional fees.
The higher cost base produced a $5.4 million quarterly net loss, or $0.60 per common share, versus a $1.7 million net loss, or $0.25 per common share, in the prior-year quarter. Other income also declined to $112,000 from $154,000, primarily because reimbursement funding from the Canadian government's Strategic Response Fund decreased. For the nine months ended June 30, 2026, net cash used in operating activities was $ (7,186,629 ), while financing activities provided 6,793,376.
Liquidity disclosed in the release was $10.3 million of cash and cash equivalents and $6.9 million of working capital at June 30, 2026. The balance sheet also showed current liabilities of $ 3,910,041, compared with $ 1,078,536 at September 30, 2025. No capital-return actions, debt amount, free cash flow, revenue guidance or formal financial outlook were provided.
The respiratory program remains the second central development focus. Edesa said exploratory analyses in ARDS patients with concurrent acute kidney injury associated paridiprubart plus standard of care with significant mortality reductions and concordant improvement in MAKE30. The company is evaluating potential regulatory pathways in major markets and pursuing strategic discussions for the program. The key near-term execution items are EB06 enrollment, expansion to additional jurisdictions, paridiprubart regulatory and partnering progress, and operating-spend progression as trial execution begins.
Management, verbatim
Our third quarter marked an important operational inflection point for Edesa, with the completion of preparations for our Phase 2 vitiligo study keeping us on track for initial enrollment in the coming weeks.
Par Nijhawan, MD, Chief Executive Officer of Edesa
In addition, the positive exploratory data in patients with acute kidney injury further reinforce the versatility of paridiprubart and support our engagement with potential partners as we advance late-stage development and evaluate future commercialization pathways.
Par Nijhawan, MD, Chief Executive Officer of Edesa
We are prioritizing execution of the EB06 Phase 2 study while continuing to support regulatory, manufacturing and business development activities for paridiprubart.
Peter Weiler, Edesa’s Chief Financial Officer
Not in the filing
stated, not guessed- Revenue and revenue comparisons were not reported.
- Revenue segments and segment revenue comparisons were not reported.
- Gross profit, gross margin and gross-margin comparisons were not reported.
- Operating income was not reported; the filing reported loss from operations.
- Non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, were not reported.
- Prior-quarter comparisons for reported operating metrics were not reported.
- Free cash flow was not reported.
- Debt was not reported.
- Share repurchases, dividends and other capital-return actions were not reported.
- Formal numerical financial guidance for revenue, gross margin, operating expenses, tax rate or other financial metrics was not reported.
- A previous-quarter outlook was not provided.
- A tax rate was not reported.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.